论文部分内容阅读
目的探讨胃癌Ｃ－ｅｒｂＢ－２癌基因扩增的临床意义。方法应用差别ＰＣＲ技术检测Ｃ－ｅｒｂＢ－２在８３例胃癌及１０１个转移淋巴结扩增情况。结果２８．９％（２４／８３）的胃癌存在该基因扩增，进展期胃癌及伴淋巴结转移者扩增阳性率增高（Ｐ＜０．０５及Ｐ＜０．０１）；转移淋巴结扩增阳性率明显高于胄癌原发灶（Ｐ＜０．０５）。早期胃癌及高中分化胃癌伴Ｃ－ｅｒｂＢ－２扩增者５年生存率低于不扩增者（Ｐ＜０．０５）。用Ｓｏｕｔｈｅｒｎｂｌｏｔ分子杂交及免疫组化ＡＢＣ法检测原胃癌样本基因扩增及过度表达，扩增及过度表达率分别为１５．７％及１８．１％，均明显低于上述扩增阳性率。结论差别ＰＣＲ技术检测Ｃ－ｅｒｂＢ－２扩增是一种快速方便、可靠、独立的方法，对胃癌预后及转移潜力是一种良好的判断指标。
Objective To investigate the clinical significance of C-erbB-2 oncogene amplification in gastric cancer. Methods Differential PCR was used to detect the amplification of C-erbB-2 in 83 cases of gastric cancer and 101 metastatic lymph nodes. Results The gene amplification was found in 28.9% (24/83) of gastric cancers, and the positive rate of lymph node metastasis was significantly higher in patients with advanced gastric cancer and those with lymph node metastasis (P <0.05 and P <0.01). Positive lymph node metastasis The rate was significantly higher than that of carcinoma (P <0.05). The 5-year survival rates of patients with advanced gastric cancer and high-differentiated gastric cancer with C-erbB-2 were lower than those without (P <0.05). The gene amplification, overexpression, amplification and overexpression rates of gastric cancer samples were 15.7% and 18.1% respectively by Southern blot hybridization and immunohistochemical ABC method, which were significantly lower than those of the above amplification. Conclusion The differential PCR detection of C-erbB-2 amplification is a fast, convenient, reliable and independent method for the prognosis and metastasis potential of gastric cancer is a good indicator.